Abstract: A method is provided for determining pulmonary embolism and/or increased risk thereof in a human being, comprising collecting a sample of exhalation air from said human being and determining the presence or absence in said exhaled air of one or more biomarkers associated with pulmonary embolism. Additionally, a kit that comprises the means for detecting at least one biomarker associated with pulmonary embolism or risk thereof is provided.

Abstract: A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.

Abstract: Aspects of the present disclosure relate to genetically altered LysM receptors. In particular, the present disclosure relates replacement of part or all of motifs in the LysM1 domain with the corresponding motifs of the LysM1 domain from a donor LysM receptor that can alter the affinity, selectivity, and/or specificity for an oligosaccharide, particularly for Nod factors (lipochitooligosaccharides (LCOs)). The present disclosure also relates to genetically altering LysM receptors in plants to include a modified LysM1 domain and to genetically altering LysM receptors in plants by replacement of part or all of motifs in the LysM1 domain. The present disclosure further relates to combining LysM1 domain modifications with modifications of LysM2 domains to include a hydrophobic patch or alter the hydrophobic patch, whereby the LysM2 domain modifications can alter the affinity, selectivity, and/or specificity for an oligosaccharide, particularly for Nod factors (lipochitooligosaccharides (LCOs)).

Abstract: The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders.

Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well 5 as methods of treating disorders associated with complement activation.

Abstract: Aspects of the present disclosure relates to genetically altered LysM receptors. In particular, the present disclosure relates to a hydrophobic patch into the LysM2 domain which can increase affinity and/or selectivity for LCOs and by replacement of regions in the LysM1 domain with the corresponding regions of the LysM1 domain from a donor LysM receptor that can alter the affinity and/or selectivity for the oligosaccharide particularly for LCOs and can alter the specificity between LCO when using regions from a high affinity and specificity LCO LysM receptor such as a legume NFR1 receptor. The present disclosure also relates to genetically altering LysM receptors in plants to include a hydrophobic patch or alter the hydrophobic patch and to genetically altering LysM receptors in plants by replacement of regions in the LysM2 domain.

Abstract: The present invention relates to the use of a composition comprising a helminth product for prevention, treatment and/or amelioration of a clinical condition associated with the RIG-LISTING and TLR pathways. Specifically, the composition is provided for use in the treatment of clinical conditions associated with constitutive activation of type I interferon (IFN), including monogenic type I interferonopathies and inflammatory or autoimmune disorders. The present invention also relates to different methods of manufacturing a helminth product.

Abstract: Aspects of the present disclosure relate to genetically modified plants comprising a nucleic acid sequence encoding a heterologous receptor polypeptide. The plants are able to recognize lipo-chitooligosaccharides (LCOs) through the heterologous receptor polypeptide. Other aspects of the present disclosure relate to methods of making such plants.

Abstract: Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders.

Abstract: The present invention relates to a transgenic pig comprising a mutated IAPP gene and displaying a phenotype associated with diabetes. The invention also relates to a transgenic blastocyst, embryo, fetus, donor cell and/or cell nucleus derived from said transgenic pig. The invention further relates to use of the transgenic pig as a model system for studying therapy, treatment and/or prevention of diabetes.

Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: The present invention relates to a method for estimating perfusion indices (PI) in a mammal (200), e.g. a human. Data (DAT, DAT?) representative of a contrast agent concentration as a function of time of an injected contrast agent is obtained from a medical imaging system (100). Perfusion indices (PI) are found by applying a parametric model (PM) for capillary transit time distributions as a function of time, and a minorize-maximization (MM) type procedure, such as an expectation-maximization (EM) type procedure, with regularization. The minorize-maximization type procedure has an exact analytical expression for the variance of an observation error of the contrast agent (C?) in a non-linear observation model for the contrast agent concentration used in the maximization step. Clinical tests performed for 7 patients show improved MTT mapping as compared to singular value decomposition (SVD), and reduced sensitivity to delay.

Abstract: The present invention relates to glycosylated YghJ polypeptides from or derived from enterotoxigenic Escherichia coli (ETEC) that are immunogenic. In particular, the present invention relates to compositions or vaccines comprising the polypeptides and their application in immunization, vaccination, treatment and diagnosis of ETEC.

Abstract: The present disclosure relates to a method and a system for modelling a human heart and/or chambers and cavities therein, such as the left and right atrium, based on a plurality of emission tomography images, such as positron emission images, of said human heart, wherein each image represents concentrations of a tracer that has been injected at a specific time, the overall method comprising the steps of: A: extracting time activity curves of a tracer that has been injected for a plurality of pixels and/or voxels; B: identifying first-pass peaks of the time activity curves, each peak corresponding to an arrival time of the injected tracer at the corresponding pixel/voxel; C: defining a model comprising at least two portions of the heart, wherein the at least two portions are isolated by selecting pixels and/or voxels based on comparisons of the first-pass peaks against a threshold; and D: arranging the at least two portions in relation to each other by comparing the arrival times of the first-pass peaks of the

Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.

Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, mi R-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, mi R-374b-5p, miR-615-3p and mi R-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.

Abstract: A method is provided of treating, preventing or ameliorating type 2 diabetes and/or a clinical condition associated with type 2 diabetes, which method comprises administering an effective amount of cafestol or a derivative thereof including esters and salts thereof to a person in need thereof. Further provided are compositions comprising cafestol and at least one additional agent suitable for treating, preventing or ameliorating diabetes and/or a clinical condition associated with diabetes. A method is also provided of increasing insulin secretion and/or increasing insulin-dependent glucose uptake, said method comprising administering an effective amount of cafestol or a derivative thereof to a person in need thereof.

Abstract: The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for the treatment of obesity.

Abstract: The present invention provides a positively charged co-polymer for use as an antimicrobial agent, wherein said positively charged co-polymer is composed of amino acids and/or derivatives thereof and wherein at least 75 molar percent of said amino acids are selected from the group consisting of alanine, lysine, glutamate, arginine and tyrosine and/or derivatives thereof. The present invention also provides methods for treating, preventing or ameliorating a microbial infection comprising administration of positively charged random co-polymers as well as a pharmaceutical composition comprising said co-polymer. The invention further provides a kit of parts comprising the positively charged random co-polymer.